Sad Diego-based CURx Pharmaceuticals has announced a global license agreement with Gilead Sciences for development of Fosfomycin/Tobramycin for Inhalation (FTI) to treat Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients. Gilead initiated a Phase 2 study of the product, then known as GS 9310/11 in late 2008, and CURx says that FTI is ready for Phase 3 trials.
CURx Founder and CEO Dinu Sen said “This is a great acquisition for CURx Pharmaceuticals which enables us to expand our portfolio and also to provide another inhaled therapeutic to the cystic fibrosis community. Clinical trials in CF patients with Pseudomonas aeruginosa infection have demonstrated FTI’s safety and efficacy. Future trials may pave the way for its use against a range of bacterial infections in CF – there is an unmet need for antibiotics with such characteristics.”
Read the CURx press release.
